Adjuvant Radiotherapy and Combined Adjuvant Treatment Strategy for UTUC - Trial NCT06120374
Access comprehensive clinical trial information for NCT06120374 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University First Hospital
Timeline & Enrollment
N/A
Oct 30, 2023
Oct 30, 2028
Primary Outcome
PFS
Summary
This study is an ambispective cohort observational study to analyze the efficacy of surgery
 alone versus postoperative adjuvant therapy (postoperative radiotherapy/postoperative
 chemotherapy(immunotherapy)/ combined strategy) in patients with the upper urinary tract
 urothelial carcinoma with high-risk factors (postoperative pathology suggestive of pT2 and
 above, N+, G3/high-grade and multiple tumors, positive cut margins). A subgroup analysis was
 performed to obtain the population of patients who might benefit from different treatment
 approaches. Patients with high risk factors for postoperative recurrence or metastasis will
 be treated with relevant adjuvant therapy, which in turn will benefit patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06120374
Non-Device Trial